Eosinophilia
18
5
6
6
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
11.1%
2 terminated out of 18 trials
75.0%
-11.5% vs benchmark
11%
2 trials in Phase 3/4
67%
4 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (18)
A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression
Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial
Activation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia
Home Air Purification for Eosinophilic COPD
Natural History of Hypereosinophilia and Hypereosinophilic Syndromes
Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
A Real-world, Head-to-head Comparison of Dupilumab Versus Mepolizumab in Danish Patients With Chronic Rhinosinusitis With Nasal Polyps
Specific Versus Empirical Anthelminthic Treatment in Eosinophilia
Mepolizumab in Episodic Angioedema With Eosinophilia
Steroid Treatment for Hypereosinophilic Syndrome
Drivers of Eosinophilic COPD Exacerbations
Phase II Gleevec Idiopathic Hypereosinophilic Syndrome
Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis
Clinical Characteristics, Treatment and Prognosis of Chest Tightness Variant Asthma
Mechanistic Study of Anti-inflammatory Effects of Fevipiprant in Patients With Eosinophilic Asthma.
Clinical Characteristics and Treatment of Chest Tightness Variant Asthma
Functional Dyspepsia (FD) - Clinical Response to Montelukast in Children
Development, Validation and Evaluation of an Adult and Pediatric Eosinophilic Esophagitis Activity Index